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K-ras is currently accepted to be the most frequently mutated
oncogene in non-small cell lung cancer. In addition, tumors harbor-
ing mutant K-ras seem to be refractory to most available systemic
therapies, making K-ras an attractive target for cancer therapy. The
complexity of K-ras signaling presents many opportunities for
therapeutic targeting. A number of different approaches aimed at
abrogating K-ras activity have been explored in clinical trials.
Several of the putative K-ras-directed therapeutic agents tested have
demonstrated clinical activity. However, many of these agents have
multiple targets, and their antitumor effects may not be due to K-ras
inhibition. To date, no selective, specific inhibitor of the K-ras
pathway is available for routine clinical use.
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Activated Ras targets a number of downstream effectors,including Raf kinase, phosphoinositide 3-kinase, and
Ral guanine exchange factors (GEFs), to produce pleiotropic
cellular effects. The importance of Ras signaling in cell
growth and survival is evidenced by the importance of Ras in
oncogenesis. Several K-ras point mutations have been iden-
tified that result in constitutive activation. These mutations
are found at high frequency in a variety of human tumors,
including 20 to 40% of non-small cell lung cancer (NSCLC),
and are briefly described herein. In recent years, K-ras mu-
tations have been correlated with nonresponsiveness to epi-
dermal growth factor receptor (EGFR) inhibitors1,2 and sys-
temic chemotherapy.3
Because the role of K-ras in oncogenesis is well estab-
lished, various strategies have been developed to target K-ras
for the treatment of human cancers. These strategies have
targeted various stages of Ras signaling, ranging from inhib-
iting protein expression via antisense oligonucleotides to
blocking posttranslational modification with farnesyltrans-
ferase inhibitors to inhibiting downstream effectors. Al-
though some of these strategies have resulted in antitumor
activity, it is still unclear what role K-ras inhibition will play
in cancer therapies, because the most well-characterized Ras
inhibitors tested in clinical trials have alternative targets.
RAS MUTATIONS
This subject has been comprehensively reviewed.1 The
role of ras genes in inducing malignant transformation is sup-
ported by several lines of evidence. First, oncogenic ras but not
normal ras transfected into rodent fibroblasts renders them tu-
morigenic.3 Second, transgenic mice harboring oncogenic ras
mutations have an increased incidence of tumor formation.4
Finally, a high frequency of ras mutations has been found in a
variety of tumor types, both naturally occurring and experimen-
tally induced. Identified mutations are limited to a small number
of sites (amino acids 12, 13, 59, and 61), all of which abolish
guanosine triphosphatase (GTPase) activating protein (GAP)-
induced guanosine triphosphate (GTP) hydrolysis of the ras
proteins.
Such single-point mutations of the ras gene can lead to its
constitutive activation of ras protein. These mutated forms of ras
have impaired GTPase activity. Although they still bind GAP,
there is no “off” sign since GTPase is no longer activated. This
results in continuous stimulation of cellular proliferation. Muta-
tions are frequently limited to only one of the ras genes, and
frequency is dependent on tissue and tumor type. Thus, ras
mutations are rare in cancers of the breast, ovary, stomach,
esophagus, and prostate but are present in almost all adenocar-
cinomas of the pancreas and 50% of colon and thyroid cancers.
Mutations in NSCLC are found only in the K-ras gene, with a
frequency of approximately 40% in adenocarcinomas.5 Recent,
emerging data suggest that in NSCLC, K-ras mutations may be
particularly common in tumors from smokers, with a frequency
of almost 60%.5
Based on the evidence presented herein, K-ras clearly
plays a role in the development and maintenance of the
malignant phenotype. The fact that Ras mutations are so
prevalent in NSCLC, with K-ras mutations being the most
common, makes this an attractive therapeutic target. For the
above reasons, cancer therapy targeting K-ras is a rational
approach that would be expected to produce a clinical benefit.
APPROACHES TO K-RAS TARGETING FOR
LUNG CANCER THERAPY
Because Ras signaling is complex, there are many steps
at which to target therapies designed to interfere with Ras
signaling. Although not specifically addressed in this review,
upstream Ras activation by tyrosine kinase and other recep-
tors is an active area of pharmaceutical development given
the successes with agents targeting EGFR and vascular en-
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dothelial growth factor receptor (VEGFR) families. It is
likely that the antitumor activity of these agents is at least, in
part, due to effects on the Ras signaling pathway. In support
of this idea is the fact that tumors with ras mutations (and
therefore constitutively active with lack of dependence on
upstream signals) are resistant to EGFR inhibitors.
Herein, we focus on strategies aimed at Ras or down-
stream effectors. Conceptually, targeting K-ras dysregulation
could occur at many levels of the Ras signaling cascade,
including inhibiting Ras protein expression, inhibiting mem-
brane localization through posttranslational modification or
trafficking, blocking Ras interaction with GEFs, enhancing
Ras/GAP interactions, targeting oncogenic K-ras, or inhibit-
ing Ras effectors. The ultimate test of Ras signaling as a valid
cancer therapy would come from an agent designed to spe-
cifically target Ras dysregulation. Unfortunately, such an
agent has not yet been developed. Considerable research went
into the development of farnesyltransferase inhibitors, which
were expected to inhibit posttranslational processing and
membrane localization of Ras proteins and antisense oligo-
nucleotides against ras. These efforts were unsuccessful and
have been reviewed extensively elsewhere.6 The two prom-
ising approaches to inhibiting K-ras that are currently under
investigation involve the inhibition of the downstream pro-
teins raf kinase and mitogen-activated protein kinase
(MAPK) kinase (MEK).
RAF KINASE INHIBITORS
The raf family comprises three members: a-raf, b-raf,
and c-raf or raf-1. These proteins enable converging of
extracellular stimuli that then activate the components of the
MAPK pathway. Although linearly located downstream of
Ras, raf kinases are now known to be part of a branch point,
controlling cell proliferation and other cellular functions
through both the MAPK pathway and MAPK independent
pathways. Of the three Raf proteins, C-Raf is the most widely
expressed. C-Raf is located in the cytosol but once activated
relocates to the membrane.
Activating mutations of B-raf have been reported in
70% of melanomas and in a number of other human tumor
types, including ovarian and papillary thyroid carcinomas. A
survey of 43 cancer cell lines demonstrated that all B-raf
mutations resided in exons 11 or 15. Remarkably, 80% of
these B-raf mutations represent a single nucleotide change of
T-A at nucleotide 1796, resulting in a valine to glutamic acid
substitution at residue 600 (V600E, exon 15) in the adenosine
triphosphate binding and substrate recognition (CR3) do-
main. This substitution confers constitutive kinase activity.
This activating B-raf allele can be detected, allowing tumor
genotyping in the clinical setting. The activating mutations in
K-ras and B-raf represent the first report of a tandem activat-
ing mutation in the same signaling pathway. Taking together,
one or the other of these mutations may be present in
approximately 50% of NSCLCs. Tumors such as NSCLC,
which possess either K-ras or B-raf mutations, or overexpres-
sion receptors that signal through the ras-MAPK pathway
such as EGFR may be amenable to inhibition of the down-
stream protein MEK. Strategies for targeting Raf include (1)
antisense oligodeoxyribonucleotides that degrade the raf-1
messenger RNA and (2) inhibition of kinase activity, for
example, BAY 43-9006.
Sorafenib (Nexavar; BAY 43-9006; Bayer Pharmaceuti-
cals, Montville, New Jersey) is a multikinase inhibitor of Raf-1;
wild-type B-raf; oncogenic b-raf V600E; VEGFR-1, -2, and -3;
platelet-derived growth factor receptor ; c-Kit; Flt-3; and RET
in vitro.7,8 Sorafenib inhibited the growth of a variety of tumor
xenograft models driven by up-regulation of Raf/MEK/ERK
signaling.5 In vitro, sorafenib inhibited tumor proliferation and
angiogenesis and promoted apoptosis in several cancer cell
lines.9 Tolerability and preliminary efficacy of sorafenib were
investigated in four dose-escalation phase 1 trials in patients
with treatment-refractory, advanced solid tumors.10–13
The optimum dose was established as sorafenib, 400
mg twice daily, given in an uninterrupted schedule. In a
pivotal phase 3 trial (Treatment Approaches in Renal cancer
Global Evaluation Trial [TARGETs]) involving patients with
clear cell renal cell carcinoma, sorafenib significantly pro-
longed progression-free survival two-fold versus placebo and
was generally well tolerated. Seven patients receiving sor-
afenib had partial responses, and 78% of patients had stable
disease versus 55% receiving placebo.14 Based on these
results, sorafenib has been approved in several countries
worldwide for the treatment of renal cell carcinoma and was
granted orphan drug status in hepatocellular carcinoma (April
2006) by the Food and Drug Administration and European
Commission.
A phase 2 study in NSCLC was reported by Gatzeimeir
et al., at the American Society of Clinical Oncology 2006
Annual Meeting. Fifty-two patients with refractory metastatic
NSCLC were enrolled. Most of the patients had a perfor-
mance status of 0 to 1 (44 of 52). Fifty had been previously
treated with 1 to 2 chemotherapy regimens, including previ-
ous gefitinib therapy. Adenocarcinoma was the predominant
histologic finding in 28 patients and squamous histologic
findings were predominant in 16 patients. In this multicenter,
open-labeled, single-arm phase 2 study, sorafenib was given
at a dose of 400 mg twice daily continuously for a 28-day
cycle until progression noted by Response Evaluation Criteria
in Solid Tumors. No objective responses were seen. Stable
disease was noted in 59% of patients. The progression-free
survival was 2.7 months and the overall survival was 6.8
months. Two patients were continuing therapy at 2 years. The
most common toxic effects were diarrhea (40%) and hand
foot syndrome (37%). Four patients had a bleeding event (3
with epistaxis and 1 patient with squamous histologic find-
ings and a cavitary lesion who developed fatal pulmonary
hemorrhage after radiation, 30 days after stopping sorafenib
therapy). Baseline lower plasma VEGF levels (161 pg/mL)
were predictive of improved median survival (292 days)
compared with higher levels (161 pg/mL) (184 days) (P 
0.05). Interestingly, the patients who showed a greater de-
crease (78 pg/mL) with sorafenib treatment at day 15, cycle
1, had a shorter survival (168 days) compared with those who
showed a lesser decrease (264 days) (P 0.05). Currently, at
least two phase 3 studies are under way (in Europe and North
America). In addition to studies evaluating single-agent sor-
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afenib in the treatment of refractory NSCLC, other studies are
looking at the combination of sorafenib with both chemother-
apy and other targeted agents such as gefitinib. In a phase 1
study of sorafenib in combination with gefitinib, the combi-
nation of sorafenib at 400 mg orally twice daily and
gefitinib at 250 mg orally once daily was well tolerated and
led to tumor regression in 9 of 12 patients.15 In addition, a
large randomized study is evaluating sorafenib and che-
motherapy versus bevacizumab and chemotherapy in pa-
tients with metastatic NSCLC. Other more specific raf
kinase inhibitors are currently in phase 1 trials and results
are awaited with interest.
MEK INHIBITORS
Three MEK inhibitors have been tested in the clinic.
The first in this class, CI-1040, displayed encouraging anti-
tumor activity in phase 1 studies and progressed to phase 2
testing in patients with metastatic or inoperable breast,
colon, NSCLC, or pancreatic cancers.16 The study enrolled
67 patients, including 18 with NSCLC. Efficacy end points
were not met and development was discontinued. A sec-
ond-generation agent, PD 0325901, with higher potency
and improved pharmacodynamic properties, was intro-
duced into the clinic.17–19
Patients with advanced breast cancer, colon cancer,
NSCLC, or melanoma were treated with doses ranging from
1 mg daily to 30 mg twice daily. Drug-related adverse events
were similar to those reported for CI-1040, including rash,
fatigue, nausea, diarrhea, and vomiting. Visual changes, in-
cluding blurred vision and haloes, were reported in five
patients receiving more than 15 mg twice daily. Dose-limit-
ing toxic effects reported included rash (3 patients), cardiac
events (2 patients), and anemia, diarrhea, and mucositis (1
patient).
Encouraging evidence of antitumor activity was ob-
served in this phase 1 trial with two partial responses in
melanoma patients, and an additional eight patients (5 mela-
noma, 2 NSCLC, and 1 colon cancer) achieved stable disease
lasting for 3 to 7 months.19 Development of this compound,
however, has been stopped because of toxicity.20
The final MEK inhibitor to undergo clinical testing is
AZD6244, which has been investigated in an open-label,
multicenter, two-part phase 1 trial in patients with advanced
solid malignancies. Although there were no objective re-
sponses, stable disease was observed in 14 of 31 patients
(45%) who were assessable for response. Nine of these
patients had stable disease that lasted longer than 5 months (6
melanoma, 1 breast cancer, 1 NSCLC, and 1 thyroid). Pre-
treatment and posttreatment tumor biopsy specimens ob-
tained from 17 patients showed a mean 83% reduction in
nuclear phospho-Erk staining. These results demonstrate
AZD6244-induced target modulation within tumor tissue.21
Based on these results, multiple phase 2 studies are ongoing,
including a study in NSCLC.
In addition to the drugs described herein, there are three
other MEK inhibitors, including a backup compound to
AZD6244, that have entered the clinic.
CONCLUSIONS
Since the identification of K-ras as the transforming
agent of the Kirsten murine sarcoma virus, more than 20
years of accumulated evidence lends extensive support to the
importance of K-ras in cellular signaling, tumorigenesis, and
maintenance of the malignant phenotype in NSCLC. The
advent of EGFR inhibitors have further highlighted the im-
portance of K-ras as a negative predictor of response to
therapy. Therefore, K-ras has been an important focus for
cancer therapy. Although a number of agents interrupting
with signal transduction proteins downstream of K-ras con-
tinue to be investigated, ongoing research seeks to identify
specific and potent inhibitors of K-ras.
The validity of targeting Ras for lung cancer therapy
will not be fully realized until clinical responses are observed
using a strategy that selectively and effectively targets K-ras.
Several candidate strategies that could answer this question
have been described. Both antisense oligonucleotides and
small interfering RNAs have the potential for specific inhi-
bition, but they are currently limited by drug delivery. If
effective delivery techniques were devised, then these may be
suitable strategies. Peptidomimetics could also specifically
block oncogenic signaling. Additionally, as high-throughput
screening progresses, it is likely that small-molecule in-
hibitors will be identified that can specifically inhibit Ras
function.
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